Is Aytu BioScience Stock a Good Investment?

Aytu BioScience Investment Advice

  AYTU
To provide specific investment advice or recommendations on Aytu BioScience stock, we recommend investors consider the following general factors when evaluating Aytu BioScience. This will help you to make an informed decision on whether to include Aytu BioScience in one of your diversified portfolios:
  • Examine Aytu BioScience's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
  • Research Aytu BioScience's leadership team and their track record. Good management can help Aytu BioScience navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
  • Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Aytu BioScience's business and its evolving consumer preferences.
  • Compare Aytu BioScience's performance and market position to its competitors. Analyze how Aytu BioScience is positioned in terms of product offerings, innovation, and market share.
  • Check if Aytu BioScience pays a dividend and its dividend yield and payout ratio.
  • Review what financial analysts are saying about Aytu BioScience's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Aytu BioScience stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Aytu BioScience is a good investment.
 
Sell
 
Buy
Hold
We provide trade advice to complement the prevailing expert consensus on Aytu BioScience. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. To make sure Aytu BioScience is not overpriced, please confirm all Aytu BioScience fundamentals, including its debt to equity, and the relationship between the gross profit and target price . Please also double-check Aytu BioScience number of shares shorted to validate your buy or sell decision is consistent with all fundamental data available and that the company can sustain itself in the current economic cycle.

Market Performance

OKDetails

Volatility

DangerousDetails

Hype Condition

Over hypedDetails

Current Valuation

UndervaluedDetails

Odds Of Distress

Above AverageDetails

Economic Sensitivity

Responds to the marketDetails

Investor Sentiment

AlarmedDetails

Analyst Consensus

Not AvailableDetails

Financial Strenth (F Score)

PoorDetails

Financial Leverage

Not RatedDetails

Reporting Quality (M-Score)

Unlikely ManipulatorDetails

Examine Aytu BioScience Stock

Researching Aytu BioScience's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 27.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.68. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aytu BioScience recorded a loss per share of 1.49. The entity last dividend was issued on the 9th of December 2020. The firm had 1:20 split on the 6th of January 2023.
To determine if Aytu BioScience is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Aytu BioScience's research are outlined below:
Aytu BioScience is way too risky over 90 days horizon
Aytu BioScience appears to be risky and price may revert if volatility continues
Aytu BioScience has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 81 M. Net Loss for the year was (15.84 M) with profit before overhead, payroll, taxes, and interest of 52.89 M.
Aytu BioScience currently holds about 23.81 M in cash with (1.39 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.38.
Aytu BioScience has a poor financial position based on the latest SEC disclosures
Aytu BioScience uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Aytu BioScience. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Aytu BioScience's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
20th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

Aytu BioScience's market capitalization trends

The company currently falls under 'Micro-Cap' category with a current market capitalization of 23.61 M.

Aytu BioScience's profitablity analysis

The company has Profit Margin (PM) of 0.02 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.13 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.13.
Determining Aytu BioScience's profitability involves analyzing its financial statements and using various financial metrics to determine if Aytu BioScience is a good buy. For example, gross profit margin measures Aytu BioScience's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Aytu BioScience's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Aytu BioScience's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Aytu BioScience. Check Aytu BioScience's Beneish M Score to see the likelihood of Aytu BioScience's management manipulating its earnings.

Basic technical analysis of Aytu Stock

As of the 30th of July, Aytu BioScience shows the Downside Deviation of 5.19, risk adjusted performance of 0.1048, and Mean Deviation of 5.24. Aytu BioScience technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Aytu BioScience's insider trading activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aytu BioScience insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aytu BioScience's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aytu BioScience insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Greg Pyszczymuka over two weeks ago
Acquisition by Greg Pyszczymuka of 208 shares of Aytu BioScience subject to Rule 16b-3
 
Christopher Brooke over two months ago
Acquisition by Christopher Brooke of 7000 shares of Aytu BioScience at 1.73 subject to Rule 16b-3
 
Christopher Brooke over three months ago
Disposition of 135000 shares by Christopher Brooke of Aytu BioScience at 0.2 subject to Rule 16b-3
 
Armistice Capital, Llc over three months ago
Acquisition by Armistice Capital, Llc of 1333334 shares of Aytu BioScience at 6.0 subject to Rule 16b-3
 
Greg Pyszczymuka over three months ago
Disposition of 209 shares by Greg Pyszczymuka of Aytu BioScience subject to Rule 16b-3
 
Liu Vivian H over three months ago
Acquisition by Liu Vivian H of 6500 shares of Aytu BioScience subject to Rule 16b-3
 
Donofrio John Jr. over three months ago
Acquisition by Donofrio John Jr. of 187804 shares of Aytu BioScience subject to Rule 16b-3
 
Christopher Brooke over three months ago
Acquisition by Christopher Brooke of 7000 shares of Aytu BioScience at 1.73 subject to Rule 16b-3
 
Joshua Disbrow over three months ago
Acquisition by Joshua Disbrow of 15000 shares of Aytu BioScience at 1.3 subject to Rule 16b-3
 
Greg Pyszczymuka over three months ago
Disposition of 208 shares by Greg Pyszczymuka of Aytu BioScience subject to Rule 16b-3
 
Oki Mark K over six months ago
Acquisition by Oki Mark K of 90000 shares of Aytu BioScience at 0.23 subject to Rule 16b-3
 
Greg Pyszczymuka over six months ago
Disposition of 208 shares by Greg Pyszczymuka of Aytu BioScience subject to Rule 16b-3

Aytu BioScience's Outstanding Corporate Bonds

Aytu BioScience issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Aytu BioScience uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Aytu bonds can be classified according to their maturity, which is the date when Aytu BioScience has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Understand Aytu BioScience's technical and predictive indicators

Using predictive indicators to make investment decisions involves analyzing Aytu BioScience's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.

Consider Aytu BioScience's intraday indicators

Aytu BioScience intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Aytu BioScience stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Aytu BioScience time-series forecasting models is one of many Aytu BioScience's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Aytu BioScience's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Aytu Stock media impact

There is far too much social signal, news, headlines, and media speculation about Aytu BioScience that are available to investors today. This information is accessible both publicly - through Aytu BioScience's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Aytu-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Aytu BioScience news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Aytu BioScience relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Aytu BioScience's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Aytu BioScience alpha.

Aytu BioScience Corporate Management

Already Invested in Aytu BioScience?

The danger of trading Aytu BioScience is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Aytu BioScience is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Aytu BioScience. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Aytu BioScience is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.

Additional Tools for Aytu Stock Analysis

When running Aytu BioScience's price analysis, check to measure Aytu BioScience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aytu BioScience is operating at the current time. Most of Aytu BioScience's value examination focuses on studying past and present price action to predict the probability of Aytu BioScience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aytu BioScience's price. Additionally, you may evaluate how the addition of Aytu BioScience to your portfolios can decrease your overall portfolio volatility.